The cost-effectiveness of PCSK9 inhibitors - The Australian healthcare perspective

PCSK9i are an effective alternative for those with existing CVD or at high risk of CVD in whom statin therapy alone is ineffective, but are not cost-effective to the Australian healthcare system based on current prices.